Remember Merck makes Maxalt for headache. Headache is #1 on the FDA list of 92 symptoms from four types of seizures to coma and death. Merck with full knowledge adds aspartame to Maxalt. Then a study is done showing addi8ng aspartame causes the product to cause worse headaches. Merck refuses to remove the aspartame. Merck is linked to the New World Order and depopulation: http://www.infowars.com/articles/nwo/depopulation_linked_merck_pharma_announces_africa_plan.htm
Dr. Betty Martini, D.Hum.
Founder, Mission Possible World Health International
9270 River Club Parkway
Duluth, Georgia 30097
Aspartame Toxicity Center: http://www.holisticmed.com/aspartame
Feds Back Merck Again
By William C. Douglass, MD
Last year, Merck took a hit when two studies called into question the safety and effectiveness of the cholesterol drug Vytorin. One even linked the drug to an increased risk of cancer.
As you can imagine, a cancer diagnosis for a drug isn't exactly good for business. Seamus Fernandez, an analyst for Leerink Swann, said that the cancer issue "was an overhang for the stock, so getting it out of the way as a potential concern is a positive. It's good from the perspective of eliminating investor overhand."
Not to worry, Merck, Uncle Sam to the rescue!
In an attempt to clear the confusion over this drug, the FDA issued the following statement: "Based on the currently available information, FDA believes it is unlikely that Vytorin or Zetia increase the risk of cancer or cancer- related death, but at this time an association cannot be definitively ruled out," the agency said.
Way to take a stand there, fellas.
Of course, what everyone fails to mention is that the FDA reached this conclusion based on two studies that haven't even been completed yet. One should be finished sometime this year, and the other won't be done for two more years!
It's irresponsible and unethical to make such statements based on incomplete science especially when there's COMPLETED studies that show otherwise.
But regardless of what the research determines about the safety of these drugs, you shouldn't be taking statins to begin with because cholesterol is good for you.
How drug companies reward their best pals? Ever wonder why the same people who are supposed to protect us from bad meds are so cozy with Big Pharma? It's because they're hoping for jobs someday!
Dr. Julie Gerberding, former head of the U.S. Centers for Disease Control and Prevention, has been rewarded with a plum job from Merck, running its $5 billion vaccine division.
Merck, of course, makes Gardasil one of the dangerous vaccines the CDC relentlessly pushed even as Gerberding cultivated her Big Pharma contacts.
There's not a chance she would have landed that high-paying new gig if she had used her time at the CDC to tell the truth about vaccines like Gardasil.
And don't think for a second that her old pals at the CDC, FDA and Department of Health and Human Services haven't noticed her big reward. It's not hard for them to read the not-so-hidden message: Play nice, and we'll take care of you.
Gerberding ran the CDC from 2002 until she resigned last January. Ethics rules prohibit high-level government officials from taking jobs with the companies they used to have a hand in regulating... for a whole year. So she'll take over in late January, right after that one-year mark.
But she hasn't exactly been starving for work. She's been a busy little bee in her year off. Since you can't work directly for those companies for a year, she did the next best thing she worked as a consultant for Edelman, a PR firm with plenty of Big Pharma clients.
You've probably seen her in this role without even realizing it. She's popped up as a talking head on TV, but they never seem to mention her gig at Edelman instead, she's just referred to as "former director of the CDC."
Sounds so much more official and impartial, right? That's Big Media for you!
At least now she has a title that'll match what she's been doing all along: Selling drugs for Big Pharma.
Still not looking for a Big Pharma payday,
William Campbell Douglass II, M.D.